To asses the Impact of loco-regional treatment on survival of patients with metastatic breast cancer at first presentation.
Phase 3
Completed
- Conditions
- Health Condition 1: null- Patient with metastatic breast cancer at first presentation.
- Registration Number
- CTRI/2012/07/002805
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 350
Inclusion Criteria
Metastatic breast cancer patients with expected survival of at least one year
Exclusion Criteria
1.Patients who are not fit to receive anthracycline / taxane based chemotherapy.
2.More than two visceral organ involvements.
3.Multiple liver metastases with deranged liver function tests (SGOT/SGPT more than four times the upper normal limit).
4.Locally static or progressive disease or systemically progressive disease as shown by repeat staging investigations guided by worsening symptoms.
5.Ulceration/ fungation/ bleeding after completion of chemotherapy, which mandates surgery.
6.Expected survival of less than six months after completion of chemotherapy.
7.Unfit for anaesthesia due to metastatic disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To assess impact of loco-regional treatment on survival in metastatic breast cancer patientsTimepoint: 3 years
- Secondary Outcome Measures
Name Time Method To assess impact of loco-regional treatment on levels of VEGF, bFGF, Angiostatin, Endostatin in blood of metastatic breast cancer patients. <br/ ><br> <br/ ><br>Timepoint: 5 years